Childhood Cancer & Cell Death Team (C3 Team), LabEx DEVweCAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France.
South-ROCK Pediatric Cancer Research Center, 69008 Lyon, France.
Int J Mol Sci. 2024 Mar 15;25(6):3361. doi: 10.3390/ijms25063361.
The BMP pathway is one of the major signaling pathways in embryonic development, ontogeny and homeostasis, identified many years ago by pioneers in developmental biology. Evidence of the deregulation of its activity has also emerged in many cancers, with complex and sometimes opposing effects. Recently, its role has been suspected in Diffuse Midline Gliomas (DMG), among which Diffuse Intrinsic Pontine Gliomas (DIPG) are one of the most complex challenges in pediatric oncology. Genomic sequencing has led to understanding part of their molecular etiology, with the identification of histone H3 mutations in a large proportion of patients. The epigenetic remodeling associated with these genetic alterations has also been precisely described, creating a permissive context for oncogenic transcriptional program activation. This review aims to describe the new findings about the involvement of BMP pathway activation in these tumors, placing their appearance in a developmental context. Targeting the oncogenic synergy resulting from this pathway activation in an H3K27M context could offer new therapeutic perspectives based on targeting treatment-resistant cell states.
BMP 通路是胚胎发育、个体发生和内稳态的主要信号通路之一,多年前就被发育生物学领域的先驱们所发现。其活性失调的证据也在许多癌症中出现,具有复杂且有时相互矛盾的影响。最近,其在弥漫性中线胶质瘤(DMG)中的作用受到怀疑,其中弥漫性内在脑桥胶质瘤(DIPG)是儿科肿瘤学中最具挑战性的问题之一。基因组测序使人们对其部分分子病因有了一定的了解,在很大一部分患者中发现了组蛋白 H3 突变。与这些遗传改变相关的表观遗传重塑也被精确地描述出来,为致癌转录程序的激活创造了一个许可的环境。这篇综述旨在描述 BMP 通路激活在这些肿瘤中的新发现,并将其在发育背景下的表现。针对 H3K27M 背景下该通路激活所产生的致癌协同作用的靶向治疗可能为基于靶向治疗耐药细胞状态的治疗提供新的治疗前景。